Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Dr. Hans Merks

Principal Investigator
The focus of the Merks group is to answer key clinical questions in pediatric sarcoma treatment with the aim to improve cure and quality of life. As Chair of the European pediatric Soft tissue sarcoma Study Group (EpSSG) and Vice-Chair of the Executive Board of the EuroEwing Consortium (EEC) Merks’ aim is to coordinate, design and implement international prospective clinical trials, including translational research, focused on sarcoma across the pediatric and young adult age range. Research in pediatric sarcoma pre-eminently is a multidisciplinary collaboration including a diversity of basic, translational and clinical research partners.
  • Complex structural variation is prevalent and highly pathogenic in pediatric solid tumors

    • nov. 2024
    • Ianthe A E M, van Belzen, et al
    • Cell genomics
  • Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy

    • dec. 2022
    • Gianni, Bisogno, et al
    • Cancer
  • Patterns of Hearing Loss in Irradiated Survivors of Head and Neck Rhabdomyosarcoma

    • dec. 2022
    • Franciscus A., Diepstraten, et al
    • Cancers
  • Rhabdomyosarcoma with unknown primary tumor site

    • dec. 2022
    • Maria Carmen, Affinita, et al
    • Pediatric Blood and Cancer
  • Essential medicines for childhood cancer in Europe

    • dec. 2022
    • , et al
    • The Lancet Oncology
Bekijk alle publicaties